MedTrace Logo

Efficacy of Low Dose Sugammadex in Reversal of NMB in Laparoscopic Barbaric Surgery

NCT02713113 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2016-03-21

No results posted yet for this study

Summary

the investigators aimed to compare the efficacy and safety of sugammadex at doses of 1.5, 2, and 4 mg/ kg for the reversal of moderate rocuronium-induced neuromuscular blockade in laparoscopic bariatric surgery.

Conditions

  • Bariatric Patients

Interventions

DRUG

sugammadex reversal of neuromuscular blockade

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Ahmed H Othman, MD · ASSUIT UNVERSITY

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2016-02-29
Completion
2016-03-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02713113 on ClinicalTrials.gov